These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16550301)

  • 1. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab.
    García Aparicio AM; Rey JR; Sanz AH; Alvarez JS
    Clin Rheumatol; 2007 May; 26(5):811-3. PubMed ID: 16550301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.
    Thiéfin G; Morelet A; Heurgué A; Diebold MD; Eschard JP
    Joint Bone Spine; 2008 Dec; 75(6):737-9. PubMed ID: 18693125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity.
    Massarotti M; Marasini B
    Int J Immunopathol Pharmacol; 2009; 22(2):547-9. PubMed ID: 19505409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.
    Schnarr S; Kuipers JG; Zeidler H
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S126-9. PubMed ID: 12463462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
    Kluger N; Girard C; Guillot B; Bessis D
    Acta Derm Venereol; 2009; 89(3):332-4. PubMed ID: 19479148
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-TNF alpha therapy in spondyloarthropathy: deciding who to treat.
    Wendling D
    Joint Bone Spine; 2003 Dec; 70(6):401-3. PubMed ID: 14667546
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
    Brocq O; Plubel Y; Breuil V; Grisot C; Flory P; Mousnier A; Euller-Ziegler L
    Presse Med; 2002 Nov; 31(39 Pt 1):1836-9. PubMed ID: 12496713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept.
    Carlsen KM; Riis L; Madsen OR
    Clin Rheumatol; 2009 Aug; 28(8):1001-3. PubMed ID: 19370307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
    Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
    Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.